CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
6.74
-0.28 (-3.99%)
At close: Oct 28, 2025, 4:00 PM EDT
6.90
+0.16 (2.37%)
After-hours: Oct 28, 2025, 7:15 PM EDT
CervoMed Revenue
CervoMed had revenue of $1.76M in the quarter ending June 30, 2025, a decrease of -46.56%. This brings the company's revenue in the last twelve months to $7.78M, down -19.44% year-over-year. In the year 2024, CervoMed had annual revenue of $9.74M with 36.29% growth.
Revenue (ttm)
$7.78M
Revenue Growth
-19.44%
P/S Ratio
7.60
Revenue / Employee
$518,465
Employees
15
Market Cap
62.36M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.74M | 2.59M | 36.29% |
| Dec 31, 2023 | 7.14M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCRVO News
- 8 days ago - CervoMed to Present at the Emerging Growth Conference - GlobeNewsWire
- 20 days ago - CervoMed Drug Cut Dementia Progression Risk By 75% In Trial - Benzinga
- 20 days ago - CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies - GlobeNewsWire
- 26 days ago - CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference - GlobeNewsWire
- 5 weeks ago - CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference - GlobeNewsWire
- 7 weeks ago - CervoMed to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - CervoMed's Dementia Data Show Slowed Disease Progression - Benzinga
- 3 months ago - CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration - GlobeNewsWire